NCT01809743

Regadenoson and Adenosine

Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Lokien van Nunen · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the gold standard)and to investigate the time intervals of maximum hyperemia induced by centrally and peripherally administered Regadenoson.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Regadenoson central -central	To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
DRUG	Regadenoson peripheral - peripheral	To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
DRUG	Regadenoson central - peripheral	To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
DRUG	Regadenoson peripheral - central	To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
DRUG	Adenosine	Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.

Timeline

• Start date: 2013-01-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2013-03-13
• Last updated: 2013-11-13

Locations

1 site across 1 country: Netherlands